El Nekidy Wasim S, Hasan Haneen, Abidi Emna, Al Sayegh Layth, Dajani Ruba Z, El-Kaissi Samer, Hegazin Safa B, Mallat Jihad
Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Case Western Reserve University, Cleveland, OH, USA.
Hosp Pharm. 2025 May 21:00185787251340645. doi: 10.1177/00185787251340645.
Available data comparing the efficacy of liraglutide and semaglutide in managing weight loss is limited. The objective of this study was to compare efficacy of both drugs on weight loss. A retrospective observational cohort study conducted at our quaternary care hospital from June 2018 to July 2022. The study included adults who received either liraglutide or semaglutide during the study period. The primary outcome was weight loss, while secondary outcomes included effects on HbA1c levels and lipid profile. A total of 366 patients were analyzed (122 on liraglutide, 244 on semaglutide). The groups were comparable in mean age (51.00 ± 11.55 vs 51.16 ± 12.35 years, = 0.521) and baseline mean weight (94.7 ± 19.5 vs 94.6 ± 19.9 kg, = 0.989). After a median follow-up of 10 (6-17) months for the liraglutide group and 7.5 (6-11) months for the semaglutide group ( < 0.001), the resultant weights were 90.8 ± 19.6 kg for the liraglutide group and 91.1 ± 19.8 kg for the semaglutide group ( < 0.001) when comparing each group to its baseline separately. When comparing the weight loss achieved in each group, liraglutide achieved a median weight loss of -4 (-7 to 0) kg versus -3 (-6 to 0) kg for semaglutide ( = 0.867). The reduction in HbA1c levels with liraglutide was significantly less than with semaglutide: -0.2 (-0.5 to 0.3) versus -0.5 (-1.1 to 0.1), respectively, ( = 0.003). Both drugs significantly lowered LDL and triglycerides. Multivariable linear regression analysis confirmed no significant difference between the drugs [ -0.577, 95% CI -1.87 to 0.7; = 0.38], while baseline weight, diabetes, and SGLT2 inhibitors were significant factors affecting weight. Both liraglutide and semaglutide were effective in reducing weight, with no significant difference between the two drugs. However, semaglutide was more effective in reducing HbA1c levels.
比较利拉鲁肽和司美格鲁肽在控制体重方面疗效的现有数据有限。本研究的目的是比较这两种药物在减肥方面的疗效。2018年6月至2022年7月在我们的四级医疗医院进行了一项回顾性观察队列研究。该研究纳入了在研究期间接受利拉鲁肽或司美格鲁肽治疗的成年人。主要结局是体重减轻，次要结局包括对糖化血红蛋白（HbA1c）水平和血脂谱的影响。共分析了366例患者（122例使用利拉鲁肽，244例使用司美格鲁肽）。两组在平均年龄（51.00±11.55岁 vs 51.16±12.35岁，P = 0.521）和基线平均体重（94.7±19.5 kg vs 94.6±19.9 kg，P = 0.989）方面具有可比性。利拉鲁肽组中位随访10（6 - 17）个月，司美格鲁肽组中位随访7.5（6 - 11）个月（P < 0.001），将每组与各自基线单独比较时，利拉鲁肽组最终体重为90.8±19.6 kg，司美格鲁肽组为91.1±19.8 kg（P < 0.001）。比较每组实现的体重减轻时，利拉鲁肽的中位体重减轻为 -4（-7至0）kg，司美格鲁肽为 -3（-6至0）kg（P = 0.867）。利拉鲁肽使HbA1c水平的降低显著低于司美格鲁肽：分别为 -0.2（-0.5至0.3）和 -0.5（-1.1至0.1），（P = 0.003）。两种药物均显著降低了低密度脂蛋白（LDL）和甘油三酯。多变量线性回归分析证实两种药物之间无显著差异[β = -0.577，95%置信区间 -1.87至0.7；P = 0.38]，而基线体重、糖尿病和钠 - 葡萄糖协同转运蛋白2（SGLT2）抑制剂是影响体重的显著因素。利拉鲁肽和司美格鲁肽在减轻体重方面均有效，两种药物之间无显著差异。然而，司美格鲁肽在降低HbA1c水平方面更有效。
